Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Merck 1Q Results

Keytruda sales were $6.9 billion in the quarter, up 20% driven by increased global uptake in earlier-stage indications.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
1Q Revenues: $15.8 billion (+9%)
1Q Earnings: $4.8 billion (+69%)
Comments: Keytruda sales were $6.9 billion in the quarter, up 20% driven by increased global uptake in earlier-stage indications, including triple-negative breast cancer and renal cell carcinoma, as well as non-small cell lung cancer (NSCLC) in the U.S. Gardasil sales were up 14% to $2.2 billion. Januvia sales were down 24% to $670 million, primarily due to lower pricing and demand in the U.S., as well as ongoing generic competition. PROQUAD, M-M-R II and VARIVAX sales were up 8% to $570 million. Bridion sales were down 10% to $440 million, primarily due to generic competition in certain ex-U.S. markets. Lagevrio sales were down 11% to $350 million. Lynparza sales were up 6% to $292 million. VAXNEUVANCE sales were up 106% to $219 million driven by continued uptake for pediatric indication in the U.S. and launches in Europe. Rotateq sales were down 27% to $216 million, primarily due to timing of shipments in China and public-sector buying patterns in the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters